INDV INDIVIOR PLC Insider Trading

CFO Ryan Preblick sold 36,000 INDV shares at $37.70 via pre-arranged 10b5-1 plan; retains 284,751 shares

This sale of 36,000 shares (36.0K shares) for $1,357,200.00 ($1.4M) was executed under a 10b5-1 trading plan adopted on 2026-03-06, making it a scheduled transaction rather than a discretionary choice by Preblick. The CFO retains 284,751 shares (284.8K shares) post-transaction, representing a -11.2% reduction in his holdings. With current stock price at $38.26, the transaction occurred at $37.70, near recent trading levels, and the company maintains solid operational performance with $317,000,000.00 ($317.0M) in latest-quarter revenue and a P/E of 18.48.

Director Ryan Barbara purchased 8 shares of INDV at $31.08 on 2026-03-13, raising holdings to 5,724 shares.

Ryan Barbara, a director at Indivior Pharmaceuticals, bought 8 shares at $31.08, a minimal addition to his 5,716-share position. The transaction is modest in absolute terms, totaling $248.68 and representing a 0.1% increase to his holdings. At the current price of $31.11, INDV trades near the transaction level but significantly below its 52-week high of $36.60, having declined 15.0% from that peak. The company's fundamentals show reasonable health—$314.0M quarterly revenue, $42.0M net income, 4.3% annual revenue growth, and a P/E ratio of 11.74—but the stock's recent weakness (down 8.7% over 30 days and 12.5% over 90 days) and Barbara's prior purchase 4 days earlier on 2026-03-09 suggest opportunistic accumulation during a downturn rather than a material confidence signal.

Director Kingsley Stuart buys 940 INDV shares at $31.86; holdings rise to 5,582 shares (+20.2%)

Kingsley Stuart, a director of Indivior Pharmaceuticals, purchased 940 shares at $31.86 on 2026-03-06, increasing his position from 4,642 to 5,582 shares—a 20.2% increase in holdings. The purchase occurred at a price $0.97 below the current market price of $32.83, and within the 52-week range ($8.81–$36.60), slightly below the recent 52-week high. The company is profitable with $42.0M in net income on $314.0M quarterly revenue and a reasonable P/E of 12.39, suggesting stable fundamentals. The timing comes amid 30-day and 90-day declines of -3.0% and -8.3% respectively, placing the purchase in a period of near-term weakness relative to recent highs.

Director Ryan Barbara bought 31 shares of INDV at $32.56 for $1.0K, adding to 5.7K-share position.

Ryan Barbara, a director of Indivior Pharmaceuticals, purchased 31 shares at $32.56 on 2026-03-09, a modest addition representing +0.5% of his pre-transaction holdings. The stock currently trades at $32.83, near where he bought it, and has declined 10.3% from its 52-week high and 3.0% over the prior 30 days. In his cross-ticker track record, prior buys averaged a -3.0% return at the 30-day mark, and his sole prior purchase at INDV on 2026-01-05 also showed a -3.0% 30-day return. The company's fundamentals remain modest but stable: $314.0M quarterly revenue, $42.0M net income, 4.3% annual revenue growth, and a P/E of 12.39. The small share count and dollar value ($1.0K) suggest this is routine portfolio activity rather than a significant conviction signal.

Director Ryan Barbara bought 775 INDV shares at $35.39; part of 4-insider cluster buy in past 14 days.

Ryan Barbara (Director) purchased 775 shares at $35.39, increasing his holdings by 65.2% from 1,188 to 1,963 shares—a material accumulation for a board member. This transaction is part of a cluster pattern, with 4 other insiders also buying within the past 14 days, suggesting coordinated confidence at a price point ($35.39) very near the 52-week high of $36.60. The company's fundamentals show solid performance: $314.0M quarterly revenue, $42.0M net income, and 8.7% annual revenue growth, though the 36.25 P/E reflects a premium valuation. The clustering of director-level accumulation, combined with the substantial individual position increase, is notable for tracking insider conviction in the current environment.

Director David E. Wheadon buys 1,771 shares of INDV at $35.39; cluster of 4 other insiders buying in past 14 days

Director Wheadon purchased 1,771 shares at $35.39, increasing his holdings by 14.0% from 12,624 to 14,395 shares, while the stock trades near its 52-week high of $36.60. The buy is part of a broader cluster pattern with 4 other insiders purchasing within the past 14 days, suggesting potential coordinated conviction among leadership. Against INDVIOR's solid operational backdrop—$314.0M quarterly revenue, $42.0M net income, and 8.7% annual revenue growth—multiple insider accumulations within a tight window merit attention as a potential positive signal. Investors should monitor whether this cluster activity continues and track the stock's performance to assess the durability of insider positioning near historical price levels.

Director Stejbach buys 775 INDV shares at $35.39; 4 other insiders bought within 14 days, cluster pattern emerges

Director Mark Stejbach purchased 775 shares of INDIVIOR PLC at $35.39 on 2026-01-05, increasing his holdings from 16,072 to 16,847 shares. This transaction occurs within a cluster pattern: 4 other insiders bought shares within the same 14-day window, suggesting coordinated or synchronized confidence signals among the insider cohort. The buy occurs near the company's 52-week high of $36.60 (trading at $35.89 currently, -1.9% from peak), at a time when INDV has appreciated 48.6% over 90 days. With a P/E of 36.25 and recent quarterly revenue of $314,000,000 with net income of $42,000,000, the company is trading at a premium multiple; the cluster buying pattern amid strong recent price momentum warrants attention to whether insiders are signaling fundamental strength or riding momentum.

Director Ninivaggi bought 775 INDV shares at $35.39; 4 other insiders also bought within 14 days (cluster pattern)

Director Daniel A. Ninivaggi purchased 775 shares of INDIVIOR PLC at $35.39 on 2026-01-05, raising his holdings to 16,923 shares from 16,148 shares. This transaction occurs as part of a cluster buy pattern with 4 other insiders purchasing within the same 14-day window. The company shows solid fundamentals with $314,000,000 in latest quarterly revenue, net income of $42,000,000, and 8.7% annual revenue growth. The stock is trading at $35.89, near its 52-week high of $36.60, and has appreciated 48.6% over the past 90 days. Concurrent insider buying across multiple company officials suggests aligned confidence in the company's valuation and outlook at current price levels.

Director Humphreys Keith buys 775 INDV shares at $35.39; 4-insider cluster pattern in 14 days; holdings +15.4%

Director Humphreys Keith purchased 775 shares at $35.39, increasing his position by 15.4% to 5,802 shares post-transaction. This open-market buy occurs within a cluster pattern: 4 other insiders have also purchased within the past 14 days, indicating coordinated board or executive interest at current price levels near the 52-week high of $36.60. The company's fundamentals show solid growth (annual revenue growth +8.7%, net income $42.0M on $314.0M quarterly revenue) and a market cap of $4.5B, though the elevated P/E of 36.25 reflects current valuation expectations. The clustering of insider purchases across multiple executives within a tight timeframe warrants investor attention to board confidence signals, particularly given the stock's recent strength (+48.6% over 90 days).